1. Introduction {#s0005}
===============

Hemoglobinopathies, including sickle cell anemia and α-/β-thalassemia, are the most common monogenic diseases worldwide ([@bb0065]). Approximately 340,000 children with significant hemoglobin (Hb) disorders are born worldwide each year, 90% of whom are in developing and low-income countries, where they represent a massive public health burden ([@bb0165]). Prevention programs based on carrier screening and prenatal diagnosis have resulted in a continuous decline in rates of thalassemia major at birth in the Mediterranean region ([@bb0015]). Such prospective screening has recently been introduced in at-risk countries in Asia ([@bb0010], [@bb0015]). Because the identification of high-risk couples by carrier testing is necessary for effective prevention, prevention programs must determine how to perform comprehensive carrier screening in large populations.

A traditional routine strategy for thalassemia carrier screening first identifies people with phenotypic traits associated with thalassemia by using hematological and biochemical tests and subsequent molecular genetic testing in this selected group to generate definitive diagnoses ([@bb0015], [@bb0145]). However, a phenotypic screening approach in carrier testing would not detect individuals with "silent" forms of thalassemia, most of whom may be missed because they have normal or borderline red cell indices and/or HbA~2~ levels ([@bb0105], [@bb0145]). In addition, the characterization of disease-causing defects in samples from individuals suspected of having thalassemia may require various labor-intensive methodologies ([@bb0015], [@bb0145]). At least 1530 mutations causing thalassemia or abnormal hemoglobin variants, ranging from single-base changes to large rearrangements, have been characterized to date ([@bb0055]). Moreover, several variants that modify β-thalassemia phenotypes have been identified at various loci ([@bb0040], [@bb0120], [@bb0135]). The application of high-throughput molecular approaches to direct mass screening and accurate molecular diagnosis of hemoglobinopathies raises several challenges.

Next-generation sequencing (NGS) has been shown to allow rapid, multiplex and high-throughput detection of genetic variants ([@bb0070]). NGS technologies---applied to the whole genome, the exome, or targeted gene panels---have been effectively used in research settings, as well as in clinical testing and diagnosis of genetic disorders ([@bb0125], [@bb0175]). Recently, target capture and NGS have been validated in patient-based and population-based carrier testing of Mendelian recessive diseases, thereby yielding high-quality genotype calls and acceptable false-positive and false-negative rates and cost-effectiveness ([@bb0020], [@bb0050]).

Here, to evaluate whether NGS might be suitable for application in clinical management of monogenic diseases in a large-scale population, we retrospectively analyzed 2522 subjects with various hemoglobinopathies by using a targeted NGS approach and validated this assay for carrier testing of multiple genetic defects in a cohort of 20,222 individuals pre-typed by routine screening methods. A population-based study of hemoglobinopathies in southern China was also performed. Our results demonstrated that NGS, compared with traditional methods, can detect pathogenic or likely pathogenic variants in a more precise and general manner, thus providing an effective platform for molecular screening and clinical genotyping in subjects with hemoglobinopathies.

2. Materials and Methods {#s0010}
========================

2.1. Study Participants {#s0015}
-----------------------

The study was approved by the Medical Ethics Committee in accordance with the Declaration of Helsinki. The study methodology was designed with guidance by STROBE ([@bb0030]).

Samples from two groups of subjects were collected for this study. In Group I, 2522 subjects included 2087 samples used for study methodology of NGS assay and the sample data of 435 Thalassemia Intermedia (TI)/Thalassemia Major (TM) patients from our previous cohort ([Fig. 1](#f0005){ref-type="fig"}) ([@bb0080]). The 2087 subjects were from China and Malaysia and included 49 normal controls and 2038 clinical samples with various hemoglobinopathies (Table S1 in the Supplementary appendix). They were used for assessing the performance of the NGS-based assay in detecting hemoglobinopathy-causing mutations in a retrospective study. The 49 controls had been sequenced previously, and they did not carry any pathogenic or likely pathogenic variants. The 2038 clinical samples had been analyzed by traditional molecular genotyping techniques (See the "[Genotypic Analysis Using Traditional Methods](#s0030){ref-type="sec"}" section). NGS analysis was performed on these pre-typed results with blinding, and the results were subsequently compared with the pre-typed results to obtain the concordance rate. Sanger sequence analysis and multiplex ligation-dependent probe amplification (MLPA) were performed to verify samples with discrepancies. Because some modifier genes had been shown to be responsible for modifying β-thalassemia phenotypes, we also analyzed whether genotypes at these loci might assist in β-thalassemia diagnosis in 1182 β-thalassemia patients with thalassemia major (TM) or thalassemia intermedia (TI; 747 patients of the 2087 samples described above and 435 patients from the cohort described in a previous study by our group ([Fig. 1](#f0005){ref-type="fig"}; [@bb0080]). Among the 747 samples, 510 were β^0^/β^0^, and 237 were β^0^/β^+^. Among the 435 samples, 300 were β^0^/β^0^ and 135 were β^0^/β^+^. In total, the 1182 samples included 810 β^0^/β^0^ and 372 β^+^/β^0^.Fig. 1The sample composition of Group I. A total of 2522 clinical samples with hemoglobinopathies were used in our study. The composition and application of these samples in this study are shown. Among them are included 1182 samples with TM or TI, which were included to evaluate SNP effects on clinical severity. The data from 435 TI/TM samples were collected from a cohort from our previous report, which had been thoroughly sequenced by NGS ([@bb0080]). Among the 747 samples, 510 β^0^/β^0^ patients were first used to identify the SNPs that might elevate HbF levels (see Fig. S6).Fig. 1

Group II, which included a total of 10,111 couples (either before or during pregnancy) were randomly selected from five provinces (Guangxi, Guandong, Yunnan, Guizhou and Hainan) in southern China ([Fig. 2](#f0010){ref-type="fig"}). The age range of these samples was 18--48 years old. We applied the assay in a blind analysis for carrier testing on these couples, who were also enrolled in prevention programs for thalassemias using traditional screening methods (See the "[Hematological Analysis](#s0025){ref-type="sec"}" and "Genotypic [Analysis Using Traditional Methods](#s0030){ref-type="sec"}" sections). They were also included in an epidemiological survey of hemoglobinopathies.Fig. 2The regional and ethnicity distribution of the 20,222 population samples from five provinces in southern China. Among the 20,222 individuals, 4622 were from Guangdong Province, 4834 were from Guangxi Province, 4082 were from Guizhou Province, 2720 were from Hainan Province and 3964 were from Yunnan Province. The ethnic groups of these samples are also listed.Fig. 2

2.2. Thalassemia Genotype Definition and Clinical Diagnosis in Thalassemia Patients {#s0020}
-----------------------------------------------------------------------------------

*HBB* genotype categories are defined as follows: (β^0^): HBB:c.124_127delTTCT, HBB:c.52A \> T, HBB:c.316-197C \> T, HBB:c.216_217insA, HBB:c.92 + 1G \> T, HBB:c.130G \> T, HBB: c.84_85insC, HBB:c.91A \> G, HBB:c.45_46insC, HBB:c.165_177delTATGGGCAACCCT, HBB:c.315 + 1G \> A, HBB:c.287_288insA, HBB:c.113G \> A, HBB:c.93-1G \> C, Chinese del(NC_000011.9:g.5191148_5270051del), Cantonese del(NC_000011.9:g.(5240000_5246696)\_5271087del), Taiwanese del(NC_000011.9:g.5247493_5248849del), Filipino del(NC_000011.9:g.5134113_5252589del), β7.3k del(NC_000011.9:g.5247824_5255222del), β21k del (NC_000011.9:g.5246909_5268823del), β118kdel (NC_000011.9:g.5135464_5254173del); (β^+^): HBB:c.-78A \> G, HBB:c.79G \> A, HBB:c.-79A \> G, HBB:c.315 + 5G \> C, HBB:c.-140C \> T, HBB:c.-81 A \> C, HBB:c.93--21G \> A and SEA-HPFH(NC_000011.9:g.5222878_5250288del). *HBA* genotype categories are defined as: -α: -α^3.7^(NC_000016.9:g.223300_227103del) and -α^4.2^(NC_000016.9:g.219817\_(223755_224074)del); \--: \--^SEA^(NC_000016.9:g.215400_234700del) and \--^Thai^(NC_000016.9:g.199800_233300del); α^T^α: α^CS^α (Hb Constant Spring. HBA2:c.427T \> C), α^Westmead^α (Hb Weastmead, HBA2:c.369C \> G), α^QS^α (Hb Quong Sze, HBA2:c.377T \> C), α^Q-thailand^α (HBA1:c.223G \> C) and α^Binyang^α (HBA2:c.40G \> T).

The definitions of TM and TI in this study were based on the following clinical indications as described previously ([@bb0130], [@bb0140]): (1) onset age \< 24 months (TM), or onset age ≥ 24 months (TI); (2) transfusion times per year \> 4 (TM), or transfusion times per year ≤ 4 (TI); (3) Hb F \< 20 g/L (TM), or Hb F ≥ 20 g/L (TI). The Hb F level was measured before transfusion.

2.3. Hematological Analysis {#s0025}
---------------------------

Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).

2.4. Genotypic Analysis Using Traditional Methods {#s0030}
-------------------------------------------------

Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The following genotyping techniques were used: Gap-PCR and multiplex ligation-dependent probe amplification (MLPA) for CNVs, reverse dot blot (RDB), high-resolution melting analysis (HRMA) and Sanger sequencing for SNVs. All techniques were performed according to standard procedures.

The genotypes of 2087 samples (49 normal controls and 2038 clinical samples with various hemoglobinopathies) were analyzed with Gap-PCR, MLPA, RDB and Sanger sequencing methods. The additional mutations detected by the NGS assay, which are listed in Supplementary Table S5, were subsequently validated by Gap-PCR, MLPA and Sanger sequencing methods.

The genotypes of selected samples from the 20,222 individuals were analyzed by using Gap-PCR, MLPA, HRMA and Sanger sequencing methods. The additional mutations detected by the NGS assay were subsequently confirmed by MLPA and Sanger sequencing.

2.5. Design of the NGS Assay {#s0035}
----------------------------

We targeted the entire protein-coding regions, key regulatory regions, known pathogenic copy number variants (CNVs) regions and single nucleotide variants (SNVs)/insertion and deletion variants (indels) in the non-coding regions of hemoglobin gene clusters (α- and β-globin gene clusters) and 4 modifier genes (*KLF1*, *BCL11A*, *HBS1L* and *MYB*). We used 21 autosomal SNP sites and 6 sex chromosomes genes as markers for identity and sex tracing of the samples. The total size of the targeted sequences was 275,234 bp. (Details are shown in Fig. S1--S3 and the "Protocol of NGS assay" section in the Supplementary appendix).

2.6. Genomic DNA Extraction and DNA Quality Characterization for NGS {#s0040}
--------------------------------------------------------------------

Genomic DNA was extracted automatically from periphery whole blood with a MagPure Buffy Coat DNA Midi KF Kit (Magen, China). DNA sample quality and quantity were measured using gel electrophoresis and/or a NanoDrop spectrophotometer (Thermo Scientific, USA).

2.7. Library Preparation and Sequencing {#s0045}
---------------------------------------

We initially established a standard method based on mechanical fragmentation, which required multiple steps for the preparation of a targeted sequencing library ([@bb0005]), and used it to prepare a library for most of the archived clinical samples. Briefly, 1 μg genomic DNA per sample was sheared into fragments of 250 bp. The DNA was then purified after characterization of fragment size. End repair, A-tailing at the 3′ ends and adapter ligation was performed through pre-capture amplification. To further improve the library preparation in terms of input DNA and automation, we optimized a Tn5 transposase-based method for rapid and low-input library preparation. For each sample, approximately 50 ng DNA was fragmented into \~ 200-bp segments and barcoded using an in-house transposome system ([@bb0100]). Then, pre-capture amplification and PCR product purification was performed. Targeted sequence capture was conducted by pooling each of the 47 indexed PCR products for the two methods for libraries and hybridization with custom capture probes. The yield libraries were validated and quantified before sequencing. DNA sequencing was performed on a HiSeq2000 or 4000 sequencer (Illumina, USA) in paired-end 100-bp reads (PE100). Each sample yielded an average 0.26--0.27 GB raw data, which provided a mean sequencing depth of 178--191 folds on the targeted regions, and 97.9--98.6% of nucleotides were covered by \> 20 uniquely mapped reads (Table S2 in the Supplementary appendix).

2.8. Data Analysis and Interpretation {#s0050}
-------------------------------------

The Illumina Pipeline software program (version 1.8) was used to process the raw image data. After image processing was complete, the raw fastq data was automatically delivered to an in-house integrated pipeline named Gaea (see Fig. S4A in the Supplementary appendix), which was based on Hadoop MapReduce Technology and has been designed to accelerate the speed of data analysis for subsequent steps of bioinformatic analysis ([@bb0090]). In detail, data filtering was performed using an in-house Perl script called GaeaFastqQC to filter out the reads with low quality or from sequencing adaptors. Then, read mapping to the human reference genome (UCSC build hg19) was performed using the BWA-based software GaeaBwaStreaming. In addition, duplicate marking, indel realignment and base quality score recalibration steps were used in post-processing of the mapped reads. Finally, SNVs (missense, splice, nonsense, synonymous variants, as well as variants in introns and promoter regions, etc.) and indels were detected using GATK-based software, GaeaGenotyper, with the UnifiedGenotyper algorithm and annotated using an in-house program called BGICGAnnotation. Structural variations were detected in parallel by two individual programs, BatCNV and Breakpointer (see Fig. S4 B in the Supplementary appendix). BatCNV was based on a hidden Markov model (HMM) algorithm and was used to detect large gene deletions and duplications by analyzing changes in read depth within the targeted region. Three QC criteria were used to filter out abnormal samples at first. Then, GC correction and Batch correction were used to minimize data fluctuations. Finally, an HMM was applied to predict the most likely copy number. Breakpointer used an alternative approach based on clustering split reads to pinpoint the exact break-points of CNVs (if possible). The properly mapped paired-end reads with soft-clipped ends were collected first. The clipped ends were remapped with the BWA-MEM algorithm. Then, reads with the same clipped position and remapped position were clustered into a group. The exact breakpoint was inferred from the group\'s clipped-remapped position pair. Finally, variants were interpreted mainly on the basis of the guidelines of the American College of Medical Genetics (ACMG) and the literature ([@bb0085], [@bb0110], [@bb0115]) and were classified as pathogenic, likely pathogenic, of unknown clinical significance, likely benign or benign, on the basis of the level of evidence supporting pathogenicity (Table S3 in the supplementary appendix). Only pathogenic and likely pathogenic variants were considered reportable and have been included in the final evaluation of each individual\'s mutation carrier status. The process is summarized in Fig. S5 in the Supplementary appendix. The pathogenicity of novel variants was analyzed by experts in hemoglobinopathy and listed in "Index of the variants" section in Supplementary. Notably, the pathogenicity of variants in modifier genes was not determined according to the criteria of Table S3 since these variants themselves were not direct disease cause. However, genotypes of these genes should be considered in accurate diagnosis of β-thalassemia patients and identification of at-risk couples because modifier genes could affect the clinical severity of thalassemia ([@bb0080]).

2.9. Statistical Analysis to Identify SNPs Associated with Clinical Severity {#s0055}
----------------------------------------------------------------------------

A total of 1182 β-thalassemia patients were enrolled to identify the modifying variants that might significantly affect the clinical severity of β-thalassemia ([Fig. 1](#f0005){ref-type="fig"}). As shown in Fig. S6, a *t*-test of the 510 β^0^/β^0^ samples, was implemented in Perl (v5.16.3) to compare the mean HbF levels between the carrier and non-carrier group of each variant with frequencies over 0.01. An association study was conducted in Plink, with the HbF z-score as the dependent variable. The variants found to be significant by both *t*-test and the association study according to *p* values after Bonferroni correction were input into a Cox regression model, together with the *KLF1* functional mutations and *HBA* disease-causing mutations. The onset ages for each sample were introduced as the dependent variable in the Cox regression. Finally, the positive variants were considered to exert a significant effect on both the HbF levels and onset ages of β thalassemia patients. All statistical analyses were performed using SPSS 19.0 software. *P-*values \< 0.05 were considered significant.

3. Results {#s0060}
==========

3.1. Accurate and Comprehensive Identification of Genetic Variants Associated With Hemoglobinopathies {#s0065}
-----------------------------------------------------------------------------------------------------

In a retrospective study, we developed a comprehensive NGS-based test for hemoglobinopathies and validated its genotyping performance in 2087 samples (2038 hemoglobinopathy patients and 49 controls) pre-typed by traditional molecular testing methods (Table S1 in the Supplementary appendix). The NGS assay identified 72 hemoglobinopathy-associated variants, accurately characterizing nearly all common and several rare thalassemia mutations known to exist in Chinese populations (Table S4 in the Supplementary appendix). No hemoglobinopathy-associated mutations were detected in the 49 controls in our study cohort. In summary, we validated our target capture and NGS assays by using a large set of reference samples, which yielded high-quality genotype calls, as well as excellent concordance rates at the α- and β-globin loci ([Table 1](#t0005){ref-type="table"}). The assay identified 14 additional variants in 25 individuals (Table S5 in the Supplementary appendix). All the additional mutations were also subsequently re-typed by traditional molecular methods ([Table 1](#t0005){ref-type="table"}). The assay failed to detect only one large deletion in the α-globin cluster due to aberrant sequencing depth distribution in the CNV analysis pipeline, possibly because of low DNA quality.Table 1Performance evaluation of variant detection with an NGS-based gene panel.Table 1LocusNGS assayTraditional molecular assayConcordance rate (%)concordance (pre-typed)concordance (re-typed)Discordanceα-globin locus41744157161[a](#tf0005){ref-type="table-fn"}99.98β-globin locus4174416590100[^2][^3][^4][^5]

3.2. Wider Molecular Characterization of Patients with TM and TI {#s0070}
----------------------------------------------------------------

To assess the ability of our assay to accurately diagnose β-thalassemia patients in clinical settings, we systematically analyzed the NGS data provided by 1182 samples (810 β^0^/β^0^ TM or TI and 372 β^0^/β^+^ TM or TI; see detailed information of phenotype parameters including Hb F levels, onset of transfusion and number of transfusions per year in [Table 2](#t0010){ref-type="table"}a). In addition to the main genotypes in the *HBA* and *HBB* genes, we identified a group of single-nucleotide polymorphisms (SNPs) in four major modifier genes and cis‑element variants in the β-globin cluster that contribute to β-thalassemia ([@bb0040], [@bb0120], [@bb0135]). The cis-elements included hypersensitive sites (HS) 1--5 of the locus control region (LCR), promoter or untranslated region (UTR) of β-globin or γ-globin, etc. We first used a panel of SNPs discovered in the targeted regions to identify SNPs that might affect levels of HbF in 510 consecutive TI/TM patients with β^0^/β^0^ genotypes ([Fig. 1](#f0005){ref-type="fig"}). *KLF1* mutations, rs368698783 (*Xmn*I), rs61749494 (*BCL11A*), rs11759553 (*HBS1L-MYB*) and *HBA* disease-causing mutations were identified as the five most important ameliorators, as previously reported in other studies ([@bb0025], [@bb0035], [@bb0080]) (Fig. S6 in the Supplementary appendix). We then evaluated their effect on clinical severity in 1182 β-thalassemia patients. NGS-based genotyping was used to perform accurate molecular characterization of β-thalassemia patients by identifying disease-causing mutations and modifier variants simultaneously. As shown in [Table 2](#t0010){ref-type="table"}b, 93.3% of β^0^/β^0^ patients with none of the five variants described above would be diagnosed as having TM, whereas this probability dropped dramatically (85.7%) in carriers of any one of the variants (*p* = 0.0034). The same trend was observed for β^0^/β^+^ patients (*p* = 0.0256). Similarly, the more variants carried by β^0^/β^0^ or β^0^/β^+^ patients, the greater their chance of developing a TI phenotype. Those who carried four of the five variants would be diagnosed as having TI without exception.Table 2Summary of the phenotypic data (a) and effect of variants on the distribution of TM and TI in 1182 β-thalassemia patients (b).Table 2(a) The phenotypic dataβ^0^/β^0^ (*n* = 810)β^0^/β^+^ (*n* = 372)*p*-value[a](#tf0010){ref-type="table-fn"}Sex (n) Males:females524:286233:1390.494Clinical data TM:TI687:123230:142\< 0.001Hematological data[b](#tf0015){ref-type="table-fn"} HbF level(g/L)\
 Onset age(month)\
 Transfusion times per year12.63 ± 14.75\
13.17 ± 27.54\
12.22 ± 6.4118.39 ± 15.58\
34.85 ± 54.02\
9.03 ± 6.57\< 0.001\
 \< 0.001\
 \< 0.001  (b) Effect of variants on the distribution of TM and TINumber of variantsTotalβ^0^/β^0^ (*n* = 810)β^0^/β^+^(*n* = 372)TM (%)TI (%)*P*-valueTM (%)TI (%)*P*-value0430279 (93.3)20 (6.7)NA97 (74.0)34 (26.0)NA1471270 (85.7)45 (14.3)0.003423[c](#tf0020){ref-type="table-fn"}95 (60.9)61 (39.1)0.02563[d](#tf0025){ref-type="table-fn"}2232121 (76.1)38 (23.9)2.977E^-07^[c](#tf0020){ref-type="table-fn"}35 (47.9)38 (52.1)0.000335[d](#tf0025){ref-type="table-fn"}34217 (53.1)15 (46.9)1.771E^-11^[c](#tf0020){ref-type="table-fn"}3 (30)7 (70)0.009455[d](#tf0025){ref-type="table-fn"}470 (0)5 (100)NA0 (0)2 (100)NA5000NA00NATotal1182687123NA230142NA[^6][^7][^8][^9][^10][^11][^12]

3.3. Evaluation of Targeted NGS Assay for Its Application to Carrier Testing {#s0075}
----------------------------------------------------------------------------

A total of 10,111 pregestational or prenatal couples from multiple ethnic groups from five provinces (Guangxi, Guandong, Yunnan, Guizhou and Hainan) were enrolled for evaluation of carrier screening ([Fig. 2](#f0010){ref-type="fig"}). The couples were separately screened with the NGS-based test and traditional routine screening methods (details shown in Fig. S7 in the Supplementary appendix). We identified 186 at-risk couples by using the NGS method, compared with 151 at-risk couples by using the routine method ([Fig. 3](#f0015){ref-type="fig"}). The proportions of couples identified as being at risk for thalassemia by using the NGS method and the routine method were 1.84% (186/10,111) and 1.50% (151/10,111), respectively. We identified 35 additional couples of the 10,111 couples by using the NGS method compared with the traditional screening/molecular testing method, thus representing a 23.2% increase in the number of positive screens ([Table 3](#t0015){ref-type="table"}). Of these 35 couples, 17 were at risk for TM or TI, 13 for Hb H disease, three for TM or TI co-inherited via KLF1 variants, one for Hb Bart\'s hydrops fetalis and one for an atypical thalassemia caused by compound heterozygosity of KLF1 mutations ([Table 3](#t0015){ref-type="table"}). All mutations in the α- or β-globin cluster and *KLF1* gene were confirmed through routine molecular methods. These 35 at-risk couples were not detected by the traditional screening pipeline owing to inherent deficiencies in the procedure. These deficiencies originated from the traditional screening strategy itself, such as misleading due to phenotype analysis and limitations of routine molecular methods. Briefly, 12 couples had a negative phenotype in the first step of hematologic testing, mutations in seven couples were misdiagnosed and mutations in 16 couples were undetected ([Fig. 3](#f0015){ref-type="fig"} and Table S6 in the Supplementary appendix). The individuals showed negative phenotype had been confirmed. Interestingly, approximately half of these individuals were from the same ethnic group and lived in an isolated region of Guizhou Province. Therefore, this pattern might be related to the genetic background of a specific population.Fig. 3Comparison of couples identified as being at risk for hemoglobinopathies by using the NGS method and the traditional routine method. A total of 4180 out of 20,222 individuals tested positive with the NGS method. Of these 4180 individuals, 2506 were also identified as positive by the traditional routine method. A total of 1538 individuals were not detected by the routine method because they showed negative phenotypes, and 136 individuals were not detected because their mutations were misdiagnosed or could not be detected by the routine method. Overall, an additional 35 couples were identified as being at risk for α- and β-thalassemia using our NGS assay.Fig. 3Table 3Details of the 151 at-risk couples identified by routine methods and the 186 at-risk couples identified by NGS.Table 3Forms of hemoglobinopathy for which fetuses would be at riskNumber of couples testing positiveMajor classesGenotypesRoutineNGSHb Bart\'s(- -/- -)2526Hb Bart\'s or mild Hb Bart\'s(- -/- -) ± (β^M^/β^N^)44Hb Bart\'s/Hb H(- -/- - or - -/-α)33Hb Bart\'s/Hb H or mild Hb Bart\'s/Hb H(- -/- - or - -/-α or \--/α^T^α) ± (β^0^/β^N^)11HbH(- -/-α)5461(- -/α^T^α)1619(α^T^α/α^T^α)12(- -/-α or - -/α^T^α)34HbH or mild HbH(- -/-α) ± (β^M^/β^N)^89(- -/α^T^α)± (β^M^/β^N^)55TM or severe TM(β^0^/β^0^) ± (αα/ααα)01TM(β^0^/β^0^)1618(β^+^/β^0^)45TM or TI(β^0^/β^0^) ± (αα/-α)44(β^0^/β^0^) ± (αα/α^T^α)01(β^0^/β^0^) ± (αα/-α or -α/-α)22(β^+^/β^0^) ± (αα/-α)33(β^+^/β^0^) ± (αα/α^T^α)11(β^0^/β^0^) ± (KLF1^M^/KLF1^N^)02TI(β^+^/β^+^)11(β^++^/β^0^)01(β^0^/β^N^, ααα/αα)07(β^0^/β^N^, ααα/αα or ααα/ααα)01(β^+^/β^N^, ααα/αα)01(β^++^/β^N^, ααα/αα)01TI or Mild TI(β^+^/β^+^) ± (αα/-α or -α/-α)01(β^+^/β^N^, ααα/αα) ± (*KLF1*^*M*^*/KLF1*^*N*^)01Atypical thalassemia(*KLF1*^*M*^*/KLF1*^*M*^)01Total151186[^13]

3.4. A Population-Based Molecular Epidemiological Investigation of Hemoglobinopathies {#s0080}
-------------------------------------------------------------------------------------

We thoroughly analyzed 20,222 subjects by using an NGS assay to detect pathogenic variants for hemoglobinopathies. At total of 4840 mutant alleles from 4180 individuals were detected, thus yielding an overall variant carrier frequency of 23.93%, including 16.77% for α-thalassemia, 4.70% for β-thalassemia, 1.70% for CNV variants (1.69% associated with the α-globin cluster and 0.01% associated with the β-globin cluster), 0.43% for KLF1 variants and 0.33% for structural hemoglobin variants ([Table 4](#t0020){ref-type="table"}). Compared with a previous screening approach that was partly based on molecular testing of a few common α-thalassemia defects (-α^3.7^/, -α^4.2^/and HBA2:c.369C \> G in all samples ([@bb0170])), the NGS approach enabled us to identify an additional 586 (12.1%) mutant alleles, including 343 pathogenic copy-number variations (CNV), 114 disease-causing mutations with no phenotypic red cell changes, 87 alleles with zinc-finger mutations in KLF1, four alleles with new variants (- -^30.8^, -α^1.2^, HBA1: c.96-1G \> C and HBB: c.41C \> T) and 38 carriers co-inherited with α- and/or β-globin gene defects. We characterized 79 genetic variants of various hemoglobinopathies, including 14 types of pathogenic KLF1 mutations in a single test (see "Index of the variants" section in Supplementary appendix). KLF1 mutations and CNVs frequencies were included in this epidemiological data because of their pathogenicity or modification of the β-thalassemia phenotype ([@bb0095], [@bb0135]). The pathogenicity of new variants in α-/β-globin gene cluster (see "Index of the variants" section in Supplementary appendix) was evaluated mainly according to the criteria of "K" type in Table S3.Table 4The results of a survey of prevalence of hemoglobinopathies among 20,222 people in five provinces in southern China.Table 4**VariantsGuangdongGuangxiGuizhouHainanYunnanTotalN%N%N%N%N%N%α-thalassemia58712.7092419.113789.26122545.042776.99339116.77**(- -^SEA^/) deletion2906.273477.181593.90983.60802.029744.82(- -^THAI^/) deletion40.0950.1010.0200.0010.03110.05(- -^30.8^/) deletion\*10.0200.0000.0000.0000.0010.005(-α^3.7^/) deletion1513.272475.111202.944201.441383.4810765.32(-α^4.2^/) deletion641.381082.23411.0041915.40210.536533.23(-α^27.6^/) deletion00.0010.0200.0000.0000.0010.005(-α^21.9^/) deletion00.0020.0400.0000.0000.0020.01(-α^2.7^/) deletion00.0010.0200.0000.0000.0010.005(-α^2.4^/) deletion00.0030.0600.0000.0000.0030.01(-α^1.2^/) deletion\*00.0010.0200.0000.0000.0010.005HBA2:c.369C \> (Hb Westmead)310.671252.59120.292398.79180.454252.10HBA2:c.427T \> C (Hb CS)230.50651.34350.8660.22160.401450.72HBA2:c.377T \> C (Hb QS)120.26130.2770.17401.4700.00720.36HBA1:c.223G \> C with -α4.2 (Hb Q-Thailand)40.0920.0000.0010.0400.0070.03HBA2:c.40G \> T (Hb Binyang)00.0000.0020.0500.0010.0330.01HBA1:c.353_355dupTCA (Hb Phnom Penh)30.0610.0200.0010.0400.0050.02HBA2:c.178G \> C (Hb Zurich-Albisrieden)20.0400.0000.0000.0000.0020.01HBA1:c.99G \> A (Hb Amsterdam)00.0010.0200.0000.0000.0010.005HBA1: c.1A \> G00.0010.0200.0000.0000.0010.005HBA1: c.2T \> A00.0000.0000.0010.0400.0010.005HBA1: c.2delT00.0000.0000.0000.0010.0310.005HBA1: c.95 + 1G \> A00.0000.0000.0000.0010.0310.005HBA1: c.96-1G \> C\*00.0010.0200.0000.0000.0010.005HBA1: c.96-2A \> G00.0000.0010.0200.0000.0010.005HBA1:c.223G \> C20.0400.0000.0000.0000.0020.01**β-thalassemia1944.203226.661894.631395.111072.709514.70**HBB: c.124_127delTTCT681.471352.79952.33963.53270.684212.08HBB: c.52A \> T150.32851.76551.3520.07220.551790.89HBB: c.316 − 197C \> T461.00190.39150.750.1850.13900.45HBB: c.−78A \> G310.67280.5890.22120.4470.18870.43HBB: c.216_217insA30.0660.1200.0020.0730.08140.07HBB: c.79G \> A (Hb E)70.15150.3180.2000.00290.73590.29HBB: c.92 + 1G \> T10.0270.1400.0000.0020.05100.05HBB: c.−79A \> G00.0020.0410.0220.0700.0050.02HBB: c.130G \> T00.0030.0620.0510.0400.0060.03HBB: c.84_85insC10.0220.0410.0200.0010.0350.02HBB: c.315 + 5G \> C00.0050.1000.0000.0000.0050.2HBB: c.−100G \> A130.28140.2920.05190.7060.15540.27HBB: c.−140C \> T00.0010.0200.0000.0000.0010.005HBB: c.113G \> A00.0000.0010.0200.0000.0010.005HBB: c.45_46insG20.0400.0000.0000.0000.0020.01HBB: c.\*110T \> C00.0000.0000.0000.0010.0310.005HBB: c.-11\_-8delAAAC10.0200.0000.0000.0000.0010.005HBB: c.304G \> C (Hb Rush)00.0000.0000.0000.0010.0310.005HBB: c.316-3C \> T00.0000.0000.0000.0010.0310.005HBB: c.316-90A \> G20.0400.0000.0000.0010.0330.01Chinese del30.0600.0000.0000.0000.0030.01SEA-HPFH10.0200.0000.0000.0010.0320.01**β-thalassemia modifier110.24420.8730.07190.70120.30870.43**KLF1110.24420.8730.07190.70120.30870.43**Structural hemoglobin variants130.28190.39120.29130.48100.25670.33**HBA1: c.84G \> T (Hb Hekinan)40.0960.1240.1080.2920.05240.12HBB: c.68A \> C (Hb G-Coushatta)00.0000.0000.0000.0020.0520.01HBB: c.170G \> A (Hb J-Bangkok)20.0400.0010.0210.0400.0040.02HBB: c.341T \> A (Hb New York)50.11120.2560.1510.0450.13290.14HBB: c.34G \> A (Hb Hamilton)00.0000.0000.0030.1100.0030.01HBB: c.352C \> T (Hb Tsukumi)00.0000.0010.0200.0000.0010.005HBB: c.4G \> T (Hb Niigata)00.0000.0000.0000.0010.0310.005HBB: c.328G \> A (Hb San Diego)10.0200.0000.0000.0000.0010.005HBB:c.265C \> G(Hb Oofuna)10.0200.0000.0000.0000.0010.005HBB: c.41C \> T (New abnormal Hb)\*00.0010.0200.0000.0000.0010.005**CNV variants942.03621.28741.81250.92892.253441.70**ααα^anti3.7^/450.97310.64170.42140.51370.931440.71ααα^anti4.2^/471.02300.62561.37100.37511.291940.96αααα^69.4^/\*00.0000.0000.0000.0010.0310.005αααα^20.9^/\*00.0000.0000.0010.0400.0010.005αααα^121.2^/\*10.0200.0000.0000.0000.0010.005HKαα/00.0010.0200.0000.0000.0010.005β 67.8k dup\*10.0200.0000.0000.0000.0010.005β 204k dup\*00.0000.0010.0200.0000.0010.005**Total484023.93**[^14][^15]

4. Discussion {#s0085}
=============

In this study, we developed and validated a target-based NGS assay for molecular screening and clinical genotyping in hemoglobinopathies with a single test. Our target regions included all eight globin genes (*HBZ*, *HBA1*, *HBA2*, *HBE1*, *HBG1*, *HBG2*, *HBD* and *HBB*) and validated genetic modifiers (*KLF1*, *BCL11A* and *MYB*). Notably, although our target region was much larger than a previously reported NGS region that covers only three globin genes (*HBA1*, *HBA2* and *HBB*; [@bb0060]), the panel we designed did not include all potentially relevant genes that might affect the phenotype. However, the aim of this study was to demonstrate a practical and accurate methodology to detect variants in known genes related to hemoglobinopathies in clinical diagnosis, and not to search for novel modifier genes or sites.

Regarding genetic epidemiological investigation, we found a relatively high carrier frequency of 23.93% among individuals from the five provinces sampled ([Table 4](#t0020){ref-type="table"}), which was higher than had been previously reported ([@bb0170]). The increased carrier frequency was because we performed a thorough molecular analysis of each individual recruited for epidemiological investigation, whereas in previous studies, molecular analysis was performed only in selected individuals with positive phenotypes. The coverage of disease-causing loci was also more comprehensive in the NGS assay than the traditional genotyping assay. In addition, this is the first systematic report of molecular epidemiological data of hemoglobinopathies in Guizhou Province. Our updated epidemiological data may make local governments more aware of the severity of this disorder and more public funds might be allocated to prevention programs.

In the aspect of public prevention the birth of affected fetus, as described in [Fig. 3](#f0015){ref-type="fig"} and [Table 3](#t0015){ref-type="table"}, the traditional screening/molecular testing methods, which failed to detect 35 at-risk couples but identified by our NGS method due to additional disease-causing mutations and/or modifier mutations, may confer small risk for thalassemias in mutation-positive couples. Our assay was designed to capture key regions, such as α- and β-globin gene clusters, associated with hemoglobinopathies used for deep sequencing, which ensures the detection of any disease-conferring sequence changes in carrier screening. Unlike traditional carrier screening assays, which are designed to search for only the most common mutations within a gene, owing to cost considerations ([@bb0045], [@bb0170]), the NGS-based approach identified both common and rare, annotated and novel variants in carriers with and without thalassemic trait phenotypes, significantly improving the detection of carrier status and therefore improving the detection rate of at-risk couples.

α-Thalassemia mutations affect up to 5% of the global population and Hb H disease, caused by the loss or inactivation of three of the four functional α-globin genes, is the most common form of symptomatic α-thalassemia ([@bb0105], [@bb0155], [@bb0165]). Of the 10,111 couples screened, 104 (1%) were found to be at risk of having a baby with Hb H disease, and nearly 1/3 of these (31/104) had non-deletional Hb H disease that would require prenatal diagnosis. One of the many aims of this study was to further evaluate the outcomes in couples who were identified as being at-risk for having children with Hb H disease, thus potentially revealing critical clinical information for their potential offspring and helping clinicians provide precise genetic counseling after careful evaluation of all the known disease-causing mutations and modifier variants. The broad phenotypic diversity and high genetic heterogeneity of patients with Hb H disease ([@bb0075], [@bb0105], [@bb0155]) may make such an assay necessary. In addition, our results showed that the frequency of alpha triplication (ααα^anti3.7^ and ααα^anti4.2^) was 1.67% ([Table 4](#t0020){ref-type="table"}). Alpha triplication is not a pathogenic mutation, but the heterozygote of β thalassemia is asymptomatic, whereas the heterozygote of β thalassemia combined with alpha triplication results in a thalassemia intermedia phenotype. However, considering many couples\' eagerness to have offspring, ethical challenges remain regarding fetuses with Hb H disease or thalassemia intermedia, which is associated with late disease onset and possibly improved survival.

Considering the broad mutation spectrum and high prevalence of hemoglobinopathy-causing mutations across ethnic groups ([@bb0065], [@bb0160]), our technology may make it technically feasible to offer more effective preconception screening and diagnosis in large populations worldwide. Additional key challenges must be addressed to make this technique applicable to routine population screening, including introducing strict management policies, decreasing running costs, and improving quality control and protocol standardization such as the parameter settings and optimization of the platform. In China, a series of regulatory requirements for NGS that were recently established by the China Food and Drug Administration (CFDA) and the National Health and Family Planning Commission (NHFPC; [@bb0180]) must be followed. The major factors limiting the application of NGS are the expensive instruments, relatively high reagent cost and additional specific bioinformatics technicians. However, if applied to a large-scale population screen, the NGS strategy, compared with the traditional strategy, has a substantial advantage in time cost. In this study, the NGS had a throughput of 3000 samples per run. With the introduction of automated instruments for the entire workflow, the total run time for 3000 samples was 178 h, and the cost per sample was approximately \$30. The cost of the test could be expected to decrease by half after approximately two years with the introduction of locally produced instruments and reagents. We believe that with continuous improvements in equipment and available methods, a comprehensive panel for hemoglobinopathies could be developed in the next few years. Furthermore, to make the NGS assay achievable for routine practice in developing countries, some conditions also need improvement, such as policy and financial support from local governments, training of skilled technicians and infrastructure construction.

Standards and guidelines for preconception population carrier screening with NGS technology have been established for several common monogenic disorders ([@bb0045], [@bb0115]). The comprehensive mutation spectrum of hemoglobinopathies and the well-established quality control procedures for variant detection by target-based NGS allowed us to develop an alternative to traditional molecular testing for carrier screening. Recently, efforts have been made to establish an NGS-based workflow for the identification of disease-causing mutations in Mendelian disorders ([@bb0150]). Our study shows that NGS-based diagnostic testing can achieve rapid, multiplex and high-throughput detection of genetic variants. Here, we used hemoglobinopathies as a model, because they are the most common human monogenic diseases and are associated with multiple mutations in disease-causing genes as well as modifier genes. Advances in NGS platforms and improved ease of operation should facilitate the mechanization and automatization of this approach, which might then serve as a solution for large-scale population-based carrier screening and an effective means of controlling severe hemoglobinopathies.
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[^1]: These authors contributed equally to this study.

[^2]: This analysis was based on the mutant allele counts in the 2087 samples tested, for a total allele count of 4174.

[^3]: Concordance (pre-typed): number of alleles whose pre-typed results were consistent with the result of NGS.

[^4]: Concordance (re-typed): number of alleles whose re-typed results were consistent with the result of NGS. (NGS detected additional variants not reported in the pre-typed results. These 25(16 + 9) variants were subsequently confirmed through traditional molecular methods.)

[^5]: This allele was a mutant allele with a deletion but was diagnosed as wild-type by the NGS assay.

[^6]: Results based on *χ*^2^ analysis.

[^7]: The total number of the samples included was 1182 (sample composition shown in [Fig. 1](#f0005){ref-type="fig"}). The five variants: *KLF1* mutations, rs368698783 (*Xmn*I), rs61749494 (*BCL11A*), rs11759553 (*HBS1L-MYB*) and *HBA* disease-causing mutations.

[^8]: Abbreviations: NA, not applicable.

[^9]: *P-*value was determined by either a Kruskal-Wallis test or the *χ*^2^ test between 2 genotypes.

[^10]: Hematological data are shown as the means ± standard deviation.

[^11]: β^0^/β^0^ patients carrying variants had a significantly higher chance of exhibiting a TI phenotype than patients carrying no variants (*p* \< 0.01).

[^12]: β^0^/β^+^ patients carrying variants had a significantly higher chance of exhibiting a TI phenotype than did patients carrying no variants (*p* \< 0.01).

[^13]: Abbreviations: Hb Bart\'s, Hb Bart\'s\' hydrops fetalis; HbH, Hb H disease; TM, thalassemia major; TI, thalassemia intermedia; β^M^, mutant β-globin allele; β^N^, normal β-globin allele; *KLF1*^*M*^, mutant *KLF1* allele; *KLF1*^*N*^, normal *KLF1* allele. ±: with or without. Atypical thalassemia: mutant *KLF1* homozygotes or compound heterozygotes will show microcytic hypochromic anemia, a phenotype similar to thalassemia.

[^14]: 20,222 samples: 4622 from Guangdong Province, 4834 from Guangxi Province, 4082 from Guizhou Province, 2720 from Hainan Province and 3964 from Yunnan Province N, number of chromosomes. \*New variants identified in this study.

[^15]: A total of 4840 α- and β- and KLF1 variant chromosomes (3757 α-variants, 996 β-variants and 87 KLF1 variants) were detected, corresponding to 4180 samples (3114 carried α-variants, 758 carried β-variants, 51 carried KLF1 variants, 222 carried both α- and β- variants, 22 carried both α- and *KLF1* variants, 8 carried both β- and KLF1 variants and 5 carried α-, β- and *KLF1* variants). Of the 4180 samples, 3565 carried only one type of variant chromosome (2758 α-, 757 β- and 50 KLF1), 570 carried two types of variant chromosome (356 α + α, 187 α + β, 1 β + β, 17 α + *KLF1*, 8 β + *KLF1* and 1 *KLF1* *+* *KLF1*), and 45 carried three types of variant chromosome (33 α + α + β, 2 α + β + β, 5 α + α + *KLF1* and 5 α + β + *KLF1*).
